GlassScriptPhysician profile
Jennifer Lin
NPI 1154663466
$4,117.18
in general payments reported to CMS, 2019-2025
31 companies · $634 in 2025
The $634 reported for 2025 was more than what 85% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.72 · 2020: $162 · 2021: $1,061 · 2022: $664 · 2023: $693 · 2024: $838 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $706.77 | 2021-2023 | |
| Astellas Pharma US INC | $643.52 | 2022-2025 | Veozah |
| Pfizer INC. | $352.44 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $298.67 | 2021-2025 | |
| Amgen INC. | $282.98 | 2021-2025 | Evenity, Prolia, Prolia |
| Therapeuticsmd, INC. | $175.90 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $169.32 | 2019-2024 | Gardasil 9, Gardasil |
| Millicent US INC | $154.93 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Sumitomo Pharma America, INC. | $137.48 | 2023-2025 | Myfembree, Gemtesa |
| Myriad Women'S Health, INC. | $120.62 | 2023 | Myrisk |
| Daiichi Sankyo INC. | $107.58 | 2019-2022 | |
| Coopersurgical, INC. | $100.29 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Shield Therapeutics INC | $96.79 | 2024 | |
| Exeltis, USA INC. | $94.21 | 2021-2025 | Slynd |
| Aspira Women'S Health INC | $94.02 | 2022-2025 | Ova1 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $71.06 | 2020-2022 | |
| Evofem Biosciences, INC. | $54.23 | 2021-2023 | Phexxi |
| Sage Therapeutics, LLC | $50.68 | 2022-2025 | Zurzuvae |
| Exact Sciences Corporation | $49.08 | 2023-2024 | Cologuard Collection Kit |
| Avion Pharmaceuticals | $48.05 | 2021 | |
| Medtronic, INC. | $42.90 | 2024 | Sonicision |
| Cumberland Pharmaceuticals, INC. | $34.78 | 2024 | Kristalose |
| Medicem INC. | $33.44 | 2021 | |
| Agile Therapeutics, INC. | $32.92 | 2022 | |
| Dexcom, INC. | $29.43 | 2025 | Dexcom G6 Transmitter |
| Ferring Pharmaceuticals INC. | $28.14 | 2019-2020 | |
| Duchesnay USA Incorporated | $24.35 | 2019 | |
| Myovant Sciences INC. | $23.81 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.37 | 2025 | |
| Eisai INC. | $20.06 | 2021 | |
| Seqirus USA INC | $15.36 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.